Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago. These…
Read the full articleYou might also wanna read
Radiology vendor Nanox Imaging warns of ‘going concern’ risk as losses deepen
The publicly traded, Israel-based company reported its quarterly earnings result on June 25, including a net loss of $14.3 million, up 8% fr
Biotech NRx to sell new shares to fund growth and operations
#NRXP NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.
GSK announces it's sold 5,749,157 shares of common stock, par value of $0.01 per share of Quest Diagnostics Inc.
Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis
Myricx Bio, a cancer therapy spinout based on research carried out at the Francis Crick Institute and Imperial College London, has reached a
crick.ac.uk·5d agoBrokerage Sets SK hynix Target Below Market Price as Others Eye 4 Million Won
BNK Investment & Securities set SK hynix's target price at 1.85 million won—about 11% below the current price—while most brokerages eye targ
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
Comments
Sign in to join the conversation.
No comments yet. Be the first.